Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2007 1
2009 1
2010 2
2011 6
2012 4
2013 10
2014 12
2015 12
2016 23
2017 23
2018 28
2019 50
2020 54
2021 66
2022 71
2023 76
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Results by year

Filters applied: . Clear all
Page 1
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.
Na F, Pan X, Chen J, Chen X, Wang M, Chi P, You L, Zhang L, Zhong A, Zhao L, Dai S, Zhang M, Wang Y, Wang B, Zheng J, Wang Y, Xu J, Wang J, Wu B, Chen M, Liu H, Xue J, Huang M, Gong Y, Zhu J, Zhou L, Zhang Y, Yu M, Tian P, Fan M, Lu Z, Xue Z, Zhao Y, Yang H, Zhao C, Wang Y, Han J, Yang S, Xie D, Chen L, Zhong Q, Zeng M, Lowe SW, Lu Y, Liu Y, Wei Y, Chen C. Na F, et al. Nat Cancer. 2022 Jun;3(6):753-767. doi: 10.1038/s43018-022-00361-6. Epub 2022 Apr 21. Nat Cancer. 2022. PMID: 35449309 Free PMC article.
Small cell lung cancer (SCLC) is notorious for its early and frequent metastases, which contribute to it as a recalcitrant malignancy. ...Metastatic and KMT2C-deficient SCLC displayed both histone and DNA hypomethylation. ...
Small cell lung cancer (SCLC) is notorious for its early and frequent metastases, which contribute to it as a recalcitrant malignancy …
KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T, Schlederer M, Trachtová K, Garces de Los Fayos Alonso I, Yang J, Högler S, Sternberg C, Bystry V, Oppelt J, Tichý B, Schmeidl M, Kodajova P, Jäger A, Neubauer HA, Oberhuber M, Schmalzbauer BS, Pospisilova S, Dolznig H, Wadsak W, Culig Z, Turner SD, Egger G, Lagger S, Kenner L. Limberger T, et al. Mol Cancer. 2022 Mar 30;21(1):89. doi: 10.1186/s12943-022-01542-8. Mol Cancer. 2022. PMID: 35354467 Free PMC article.
We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients. ...Loss of PTEN and KMT2C in prostate cancer results in loss of s …
We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT …
KMT2C and KMT2D aberrations in breast cancer.
Tinsley E, Bredin P, Toomey S, Hennessy BT, Furney SJ. Tinsley E, et al. Trends Cancer. 2024 Jun;10(6):519-530. doi: 10.1016/j.trecan.2024.02.003. Epub 2024 Mar 7. Trends Cancer. 2024. PMID: 38453563 Review.
KMT2C/D are the most frequently mutated histone methyltransferases (HMTs) in breast cancer, occurring at frequencies of 10-20% collectively. ...This review provides an overview of the functions of KMT2C/D and outlines the recent clinical and experimental evid …
KMT2C/D are the most frequently mutated histone methyltransferases (HMTs) in breast cancer, occurring at frequencies of 10-20% …
Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer.
Lian J, Xu C, Chen X, Huang S, Wu D. Lian J, et al. J Cancer Res Clin Oncol. 2022 Jul;148(7):1627-1640. doi: 10.1007/s00432-022-03968-5. Epub 2022 Mar 23. J Cancer Res Clin Oncol. 2022. PMID: 35322299
This study aimed to reveal the potential carcinogenic role of KMT2C in PCa. METHODS: We first examined the expression levels of KMT2C in prostate cancer tissues. Then, we assessed the function of KMT2C in prostate cancer cell proliferation, colo …
This study aimed to reveal the potential carcinogenic role of KMT2C in PCa. METHODS: We first examined the expression levels of KM …
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Tran N, Broun A, Ge K. Tran N, et al. Mol Cell Biol. 2020 Sep 28;40(20):e00341-20. doi: 10.1128/MCB.00341-20. Print 2020 Sep 28. Mol Cell Biol. 2020. PMID: 32817139 Free PMC article. Review.
KDM6A physically associates with histone H3 lysine 4 monomethyltransferases MLL3 (KMT2C) and MLL4 (KMT2D). Since its identification as an H3K27 demethylase in 2007, studies have reported KDM6A's critical roles in cell differentiation, development, and cancer. ...Mut …
KDM6A physically associates with histone H3 lysine 4 monomethyltransferases MLL3 (KMT2C) and MLL4 (KMT2D). Since its identification a …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H. Chang S, et al. Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. Exp Mol Med. 2019. PMID: 31221981 Free PMC article. Review.
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts of cancer development. The cancer genome atlas (TCGA) project identified 299 genes and 24 pathways/biological processes that …
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts …
COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Fagan RJ, Dingwall AK. Fagan RJ, et al. Cancer Lett. 2019 Aug 28;458:56-65. doi: 10.1016/j.canlet.2019.05.024. Epub 2019 May 22. Cancer Lett. 2019. PMID: 31128216 Free PMC article. Review.
Over the past several years, large-scale tumor DNA sequencing studies have revealed the potential involvement of other KMT2 family genes, including heterozygous somatic mutations in the paralogous MLL3/KMT2C and MLL2(4)/KMT2D genes that are now among the most frequently as …
Over the past several years, large-scale tumor DNA sequencing studies have revealed the potential involvement of other KMT2 family genes, in …
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X, Qiu R, Xu M, Meng M, Zhao S, Ji J, Yang Y. Liu X, et al. Breast Cancer Res Treat. 2021 Sep;189(2):347-361. doi: 10.1007/s10549-021-06325-1. Epub 2021 Jul 8. Breast Cancer Res Treat. 2021. PMID: 34240274
RESULTS: Among the 450 epigenetic regulators, KMT2C was frequently mutated in breast cancer samples. The tumor mutational burden (TMB) was elevated in breast cancer samples with KMT2C mutations or low KMT2C mRNA levels compared to their counterp …
RESULTS: Among the 450 epigenetic regulators, KMT2C was frequently mutated in breast cancer samples. The tumor mutational burd …
Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer.
Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A, Bergholtz H, Ghamrasni SE, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lü Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD, Egan SE, Cescon DW, Sørlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK, Knudsen ES, Pujana MA, Wahl GM, Schramek D. Langille E, et al. Cancer Discov. 2022 Dec 2;12(12):2930-2953. doi: 10.1158/2159-8290.CD-21-0865. Cancer Discov. 2022. PMID: 36108220 Free PMC article.
Systematically investigating the scores of genes mutated in cancer and discerning disease drivers from inconsequential bystanders is a prerequisite for precision medicine but remains challenging. Here, we developed a somatic CRISPR/Cas9 mutagenesis screen to study 215 recu …
Systematically investigating the scores of genes mutated in cancer and discerning disease drivers from inconsequential bystanders is …
Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
Liu R, Niu Y, Liu C, Zhang X, Zhang J, Shi M, Zou W, Gu B, Zhu H, Wang D, Yuan H, Li W, Zhao D, Zheng Q, Liu R, Chen W, Ma T, Zhang Y. Liu R, et al. Cancer Sci. 2023 Apr;114(4):1229-1239. doi: 10.1111/cas.15716. Epub 2023 Jan 24. Cancer Sci. 2023. PMID: 36601880 Free PMC article.
However, there was no significant association between KMT2C/D LOF and TILs levels in other cancer types. Consistently, the results showed that KMT2C/D LOF variants were associated with prolonged overall survival only in colorectal cancer (p = 0.0485). …
However, there was no significant association between KMT2C/D LOF and TILs levels in other cancer types. Consistently, the res …
423 results